Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Spotlight
  • Published:

Molecular monitoring of response to imatinib (Glivec®) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission

Leukemia volume 17, pages 1687–1694 (2003)Cite this article

Abstract

A significant proportion of chronic myeloid leukemia (CML) patients achieve a major cytogenetic remission (MCR) to imatinib therapy after failing interferon (IFN) α-based protocols. We sought to determine levels of residual disease in patients with MCR using various molecular methods and to establish a relation between residual BCR-ABL transcript levels and rate of relapse in complete cytogenetic remission (CCR). Response was measured by conventional cytogenetic analysis, hypermetaphase and interphase fluorescence in situ hybridization (HM-FISH, IP-FISH) of bone marrow (BM) cells, qualitative nested and quantitative reverse transcriptase polymerase chain reaction (RT-PCR) for BCR-ABL transcripts. We investigated 323 peripheral blood (PB) and BM samples from 48 CML patients who achieved a complete (Ph+ 0%; n=41) or partial (Ph+ 1–34%; n=7) cytogenetic remission after 3–20 months of imatinib therapy. Prior to imatinib, 35 patients were in chronic phase (CP), eight in accelerated phase (AP), four in myeloid and one in lymphoid blast crisis. HM-FISH results correlated with ratios BCR-ABL/ABL in PB and BM. In patients with CCR, residual disease was detectable by HM-FISH (31%), IP-FISH (18%), and RT-PCR (100%). During follow-up, BCR-ABL became undetectable in two patients (one CP, one AP) by both nested and quantitative RT-PCR. CCR is ongoing in 30 evaluable patients, 11 patients have relapsed. At the time of best response, median ratios BCR-ABL/ABL were 2.1% (range 0.82–7.8) in patients with subsequent relapse and 0.075% (range 0–3.9) in patients with ongoing remission (P=0.0011). All 16 CP patients, who achieved ratios BCR-ABL/ABL <0.1% as best molecular response are in continuous remission, while 6/13 patients (46%) with ratios ⩾0.1% have relapsed (P=0.0036). We conclude that: (i) in patients with CCR to imatinib, HM-FISH and RT-PCR usually reveal residual BCR-ABL+ cells; (ii) RT-PCR results derived from PB and BM are comparable in CP CML; and (iii) low levels of residual disease with ratios BCR-ABL/ABL <0.1% are associated with continuous remission.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

References

  1. Sawyers CL . Chronic myeloid leukemia. N Engl J Med 1999; 340: 1330–1340.

    Article  CAS  PubMed  Google Scholar 

  2. Deininger MWN, Goldman JM, Lydon N, Melo JV . The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 1997; 90: 3691–3698.

    CAS  PubMed  Google Scholar 

  3. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561–566.

    Article  CAS  PubMed  Google Scholar 

  4. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645–652.

    Article  CAS  PubMed  Google Scholar 

  5. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99: 1928–1937.

    Article  CAS  PubMed  Google Scholar 

  6. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99: 3530–3539.

    Article  CAS  PubMed  Google Scholar 

  7. Hehlmann R, Heimpel H . Current aspects of drug therapy in Philadelphia-positive CML: correlation of tumor burden with survival. Leuk Lymphoma 1996; 22 (Suppl. 1): 161–167.

    Article  PubMed  Google Scholar 

  8. Kantarjian HM, O'Brien S, Cortes JE, Shan J, Giles FJ, Rios MB et al. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer 2003; 97: 1033–1041.

    Article  CAS  PubMed  Google Scholar 

  9. Bonifazi F, De Vivo A, Rosti G, Guilhot F, Guilhot J, Trabacchi E et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 2001; 98: 3074–3081.

    Article  CAS  PubMed  Google Scholar 

  10. Hochhaus A, Reiter A, Saußele S, Reichert A, Emig M, Kaeda J et al. Molecular heterogeneity in complete cytogenetic responders after interferon-α therapy for chronic myeloid leukemia: low levels of minimal residual disease are associated with continuing remission. Blood 2000; 95: 62–66.

    CAS  PubMed  Google Scholar 

  11. Cross NCP, Melo JV, Feng L, Goldman JM . An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. Leukemia 1994; 8: 186–189.

    CAS  PubMed  Google Scholar 

  12. Schoch C, Schnittger S, Bursch S, Gerstner D, Hochhaus A, Berger U et al. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and follow up in chronic myeloid leukemia: study on 350 cases. Leukemia 2002; 16: 53–59.

    Article  CAS  PubMed  Google Scholar 

  13. Kantarjian HM, Smith TL, O'Brien S, Beran M, Pierce S, Talpaz M et al. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. Ann Intern Med 1995; 122: 254–261.

    Article  CAS  PubMed  Google Scholar 

  14. Cross NCP, Feng L, Bungey J, Goldman JM . Minimal residual disease after bone marrow transplant for chronic myeloid leukaemia detected by the polymerase chain reaction. Leuk Lymphoma 1993; 11 (Suppl. 1): 39–43.

    Article  PubMed  Google Scholar 

  15. Emig M, Saussele S, Wittor H, Weisser A, Reiter A, Willer A et al. Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia 1999; 13: 1825–1832.

    Article  CAS  PubMed  Google Scholar 

  16. Cross NCP, Feng L, Chase A, Bungey J, Hughes TP, Goldman JM . Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 1993; 82: 1929–1936.

    CAS  PubMed  Google Scholar 

  17. Cross NCP . Assessing residual leukaemia. Baillieres Clin Haematol 1997; 10: 389–403.

    Article  CAS  PubMed  Google Scholar 

  18. Hochhaus A, Weisser A, La Rosée P, Emig M, Müller MC, Saußele S et al. Detection and quantification of residual disease in chronic myelogenous leukemia. Leukemia 2000; 14: 998–1005.

    Article  CAS  PubMed  Google Scholar 

  19. van der Velden VHJ, Hochhaus A, Cazzaniga G, Szczepanski T, Gabert J, van Dongen JJM . Detection of minimal residual disease in hematopoietic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia 2003; 17: 1013–1034.

    Article  CAS  PubMed  Google Scholar 

  20. Clarkson B, Strife A . Linkage of proliferative and maturational abnormalities in chronic myelogenous leukemia and relevance to treatment. Leukemia 1993; 7: 1683–1721.

    CAS  PubMed  Google Scholar 

  21. Hook EB . Exclusion of chromosomal mosaicism: tables of 90%, 95%, and 99% confidence limits and comments on use. Am J Hum Genet 1977; 29: 94–97.

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Cortes J, Talpaz M, O'Brien S, Rios MB, Majlis A, Keating M et al. Suppression on cytogenetic clonal evolution with interferon alfa therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. J Clin Oncol 1998; 16: 3279–3285.

    Article  CAS  PubMed  Google Scholar 

  23. Andersen MK, Pedersen-Bjergaard J, Kjeldsen L, Dufva IH, Brondum-Nielsen K . Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8. Leukemia 2002; 16: 1390–1393.

    Article  CAS  PubMed  Google Scholar 

  24. Meeus P, Demuynck H, Martiat P, Michaux L, Wouters E, Hagemeijer A . Sustained, clonal karyotype abnormalities in the Philadelphia chromosome negative cells of CML patients successfully treated with Imatinib. Leukemia 2003; 17: 465–467.

    Article  CAS  PubMed  Google Scholar 

  25. Bumm T, Muller C, Al Ali HK, Krohn K, Shepherd P, Schmidt E et al. Emergence of clonal cytogenetic abnormalities in Ph− cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 2003; 101: 1941–1949.

    Article  CAS  PubMed  Google Scholar 

  26. Seong DC, Kantarjian HM, Ro JY, Talpaz M, Xu J, Robinson JR et al. Hypermetaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatment. Blood 1995; 86: 2343–2349.

    CAS  PubMed  Google Scholar 

  27. Bentz M, Cabot G, Moos M, Speicher MR, Ganser A, Lichter P et al. Detection of chimeric BCR-ABL genes on bone marrow samples and blood smears in chronic myeloid and acute lymphoblastic leukemia by in situ hybridization. Blood 1994; 83: 1922–1928.

    CAS  PubMed  Google Scholar 

  28. Seong DC, Song MY, Henske EP, Zimmerman SO, Champlin RE, Deisseroth AB et al. Analysis of interphase cells for the Philadelphia translocation using painting probe made by inter-Alu-polymerase chain reaction from a radiation hybrid. Blood 1994; 83: 2268–2273.

    CAS  PubMed  Google Scholar 

  29. Akel S, Kolialexi A, Mavrou A, Metaxotou C, Loukopoulos D, Yataganas X . Efficiency of interphase fluorescence in situ hybridization for BCR/ABL on peripheral blood smears for monitoring of CML patients: a comparison with bone marrow findings. Clin Lab Haematol 2002; 24: 361–367.

    Article  CAS  PubMed  Google Scholar 

  30. Branford S, Hughes TP, Rudzki Z . Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br J Haematol 1999; 107: 587–599.

    Article  CAS  PubMed  Google Scholar 

  31. Eder M, Battner K, Kafert S, Stucki A, Ganser A, Hertenstein B . Monitoring of BCR-ABL expression using real-time RT-PCR in CML after bone marrow or peripheral blood stem cell transplantation. Leukemia 1999; 13: 1383–1389.

    Article  CAS  PubMed  Google Scholar 

  32. Lion T, Izraeli S, Henn T, Gaiger A, Mor W, Gadner H . Monitoring of residual disease in chronic myelogenous leukemia by quantitative polymerase chain reaction. Leukemia 1992; 6: 495–499.

    CAS  PubMed  Google Scholar 

  33. Mensink E, van de Locht A, Schattenberg A, Linders E, Schaap N, Guerts van Kessel A et al. Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR. Br J Haematol 1998; 102: 768–774.

    Article  CAS  PubMed  Google Scholar 

  34. Preudhomme C, Révillion F, Merlat A, Hornez L, Roumier C, Duflos-Grardel N et al. Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using a ‘real time’ quantitative RT-PCR assay. Leukemia 1999; 13: 957–964.

    Article  CAS  PubMed  Google Scholar 

  35. Hochhaus A, Lin F, Reiter A, Skladny H, Mason PJ, van Rhee F et al. Quantification of residual disease in chronic myelogenous leukemia patients on interferon-α therapy by competitive polymerase chain reaction. Blood 1996; 87: 1549–1555.

    CAS  PubMed  Google Scholar 

  36. Gabert J, Beillard E, van der Velden VHJ, Bi W, Grimwade D, Pallisgaard N et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction (RQ-PCR) of fusion gene transcripts for residual disease detection in leukaemia – an Europe Against Cancer Program. Leukemia 2003; 17: in press.

  37. Guo JQ, Lin H, Kantarjian H, Talpaz M, Champlin R, Andreeff M et al. Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients. Leukemia 2002; 16: 2447–2453.

    Article  CAS  PubMed  Google Scholar 

  38. Merx K, Müller MC, Kreil S, Lahaye T, Paschka P, Schoch C et al. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. Leukemia 2002; 16: 1579–1583.

    Article  CAS  PubMed  Google Scholar 

  39. Kantarjian HM, Talpaz M, Cortes J, O'Brien S, Faderl S, Thomas D et al. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; Gleevec) in chronic-phase chronic myelogenous leukemia. Clin Cancer Res 2003; 9: 160–166.

    CAS  PubMed  Google Scholar 

  40. Szczepanski T, Orfao A, van der Velden V, San Miguel JF, van Dongen JJ . Minimal residual disease in leukaemia patients. Lancet Oncol 2001; 2: 409–417.

    Article  CAS  PubMed  Google Scholar 

  41. Ottmann OG, Druker BJ, Sawyers CL, Goldman JM, Reiffers J, Silver RT et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002; 100: 1965–1971.

    Article  CAS  PubMed  Google Scholar 

  42. Hochhaus A, Kreil S, Corbin AS, La Rosée P, Müller MC, Lahaye T et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002; 16: 2190–2196.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We are grateful to all colleagues and nursing staff from the referring centers for participating in this study. This work was supported by the Deutsche José-Carreras-Stiftung eV, the Forschungsfonds der Fakultät für Klinische Medizin, Mannheim and the competence network ‘Acute and chronic leukemias’, sponsored by the German Bundesministerium für Bildung und Forschung (Projektträger Gesundheitsforschung; DLR e.V.).

Author information

Authors and Affiliations

  1. III. Medizinische Klinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Mannheim, Germany

    P Paschka, M C Müller, K Merx, S Kreil, T Lahaye, A Weisser, A Petzold, H König, U Berger, R Hehlmann & A Hochhaus

  2. Medizinische Klinik 3, Klinikum Grosshadern der Universität, München, Germany

    C Schoch

  3. Novartis Pharma GmbH, Nürnberg, Germany

    H Gschaidmeier

Authors
  1. P Paschka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M C Müller
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K Merx
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S Kreil
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C Schoch
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T Lahaye
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A Weisser
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A Petzold
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. H König
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. U Berger
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. H Gschaidmeier
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. R Hehlmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. A Hochhaus
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Paschka, P., Müller, M., Merx, K. et al. Molecular monitoring of response to imatinib (Glivec®) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission. Leukemia 17, 1687–1694 (2003). https://doi.org/10.1038/sj.leu.2403033

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403033

Keywords

This article is cited by

Search

Advanced search

Quick links